Drug intelligence / Profile preview

(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol

Development stage: Unknown
Modality: Small Molecules

Overview

(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol is a synthetic small molecule belonging to the class of organic compounds known as 6‑aminopurines. It is structurally related to adenine derivatives and acts as an experimental inhibitor of adenosine deaminase. This mechanism suggests potential utility in modulating purinergic signaling or immune responses, but it has not been approved for any clinical indication and remains at the experimental stage[2]. No clinical trials or approved uses are reported.

Other names: (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol79813-69-7erythro-9-(2-hydroxy-3-nonyl)adenineerythro 9-Amino-beta hexyl-alpha methyl 9H purine 9 ethanol[5]

Targets

ADA (Adenosine deaminase)

Beyond the preview

Go deeper on (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol.

Explore the full profile